End­points 11 win­ner As­cid­i­an Ther­a­peu­tics: A search-and-re­place tech­nol­o­gy comes to RNA ...

A Q&A with a No­bel Prize win­ner; Pfiz­er meets with Star­board; J&J re­ports Q3 earn­ings; and more ...

The FDA has approved Johnson & Johnson’s IL-23 blocker Tremfya to treat ulcerative colitis, a boost to the pharma’s hopes that the drug will serve as a worthy follow-up to ...

BioMarin is bringing prominent dealmaker James Sabry onto its executive team, along with Amgen rare disease veteran Greg Friberg. Sabry will start on Oct. 7 as chief business officer, following ...

GSK is handing mRNA vaccine partner CureVac €400 million ($429 million) upfront to take over full rights to the influenza and Covid vaccine candidates they have been collaborating on, while ...

#AS­CO24: A roundup of the lat­est da­ta from Merus, Mor­phoSys and oth­ers ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year ...

Sanofi has agreed to settle about 4,000 cases in the sprawling litigation over the heartburn drug Zantac and claims that it contained a carcinogen that caused cancer. On Thursday, Sanofi ...

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...

About a decade ago, David Buseck’s left foot first started dragging during a race. He chalked it up to not being much of a runner. In hindsight, he sees it ...

Reps. Kelly Armstrong (R-ND) and Ben Cline (R-VA) sent a letter last week to Attorney General Merrick Garland, asking why the Department of Justice is willing to incur potential patent ...

Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and ...